BridgeBio Oncology Therapeutics (BBOT) Non-Interest Income (2024 - 2025)
BridgeBio Oncology Therapeutics (BBOT) posted Non-Interest Income of $1159.0 for Q2 2025, down 52.6% sequentially from $2445.0 in Q1 2025.
Powered by 
Analysis
BridgeBio Oncology Therapeutics (BBOT) Non-Interest Income (2024 - 2025) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Non-Interest Income for 2 years, with the latest figure at $1159.0 in Q2 2025.
- Quarterly Non-Interest Income changed N/A year-over-year to $1159.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $1159.0 (down 86.57% YoY) and the FY2024 annual result came in at $6182.0, changed N/A from the prior year.
- Non-Interest Income retreated to $1159.0 in Q2 2025 per BBOT's latest filing, from $2445.0 in the prior quarter.
- Over five years, Non-Interest Income peaked at $3182.0 in Q4 2024 and troughed at $1159.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Interest Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | BridgeBio Oncology Therapeutics | 722.89 Mn | 497.18 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 1,159.00 |
| Mar 31, 2025 | 2,445.00 |
| Dec 31, 2024 | 3,182.00 |
| Sep 30, 2024 | 3,000.00 |